Tarsus Pharmaceuticals In... (TARS)
45.14
0.81 (1.83%)
At close: Jan 15, 2025, 1:52 PM
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
| Net Income | -135.89M | -62.09M | -13.83M | -26.81M | -4.67M | -1.32M |
| Depreciation & Amortization | 877.00K | 325.00K | 312.00K | 96.00K | 37.00K | 1K |
| Stock-Based Compensation | 19.83M | 13.46M | 8.46M | 839.00K | 18.00K | 9.00K |
| Other Working Capital | 4.30M | -1.77M | -2.51M | -1.78M | 240.00K | -5.00K |
| Other Non-Cash Items | -2.61M | 227.00K | 5.79M | 3.27M | 126.00K | -116.00K |
| Deferred Income Tax | n/a | n/a | 1.65M | 15.00K | 331.00K | n/a |
| Change in Working Capital | 306.00K | -951.00K | 1.37M | 1.46M | 485.00K | 126.00K |
| Operating Cash Flow | -117.49M | -49.03M | 3.75M | -21.14M | -3.67M | -1.18M |
| Capital Expenditures | -1.50M | -506.00K | -586.00K | -456.00K | -175.00K | -7.00K |
| Acquisitions | n/a | 144.12M | n/a | n/a | n/a | n/a |
| Purchase of Investments | -28.66M | -149.44M | n/a | n/a | n/a | n/a |
| Sales Maturities Of Investments | 174.77M | 5.32M | n/a | n/a | n/a | n/a |
| Other Investing Acitivies | -4.00M | -144.12M | n/a | n/a | n/a | n/a |
| Investing Cash Flow | 140.60M | -144.63M | -586.00K | -456.00K | -175.00K | -7.00K |
| Debt Repayment | 10.00M | 20.00M | n/a | n/a | 1.99M | n/a |
| Common Stock Repurchased | n/a | n/a | n/a | -28.00K | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 1.58M | -365.00K | 21.00K | 40.10M | 57.46M | 3.56M |
| Financial Cash Flow | 130.18M | 93.99M | 21.00K | 131.77M | 59.45M | 3.56M |
| Net Cash Flow | 153.29M | -99.67M | 3.18M | 110.18M | 55.60M | 2.37M |
| Free Cash Flow | -123.00M | -49.54M | 3.16M | -21.59M | -3.85M | -1.19M |